Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.124
Neutral
RSI(14)
40.423
Neutral
STOCH(KDJ)(9,3,3)
36.175
Sell
ATR(14)
2.964
Low Volatility
CCI(14)
-131.251
Sell
Williams %R
93.113
Oversold
TRIX(12,20)
-0.418
Sell
StochRSI(14)
0.000
Sell
Search
Spruce Biosciences Inc
SPRBAdd to Watchlist
53.780USD
-5.220-8.85%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
148.02MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Spruce Biosciences Inc
Currency: USD Updated: 2026-05-15Key Insights
Spruce Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 188 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 182.60.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Spruce Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Spruce Biosciences Inc Highlights
StrengthsRisks
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Undervalued
The company’s latest PE is -1.50, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 927.15K shares, increasing 25.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
178.600
Target Price
+202.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Spruce Biosciences Inc is 8.26, ranking 41 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.
Score
Financials
9.57
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.61
Operational Efficiency
10.00
Growth Potential
5.13
Shareholder Returns
6.99
Spruce Biosciences Inc's Company Valuation
Currency: USD Updated: 2026-05-15No valuation score is currently available for Spruce Biosciences Inc. The Biotechnology & Medical Research industry's average is 7.02. Its current P/E ratio is -1.50, which is -99.75% below the recent high of -0.00 and -9.71% above the recent low of -1.65.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 188/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Spruce Biosciences Inc is 9.00, ranking 17 out of 382 in the Biotechnology & Medical Research industry. The average price target is 209.50, with a high of 259.00 and a low of 160.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
178.600
Target Price
+202.71%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Spruce Biosciences Inc
SPRB
5
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Spruce Biosciences Inc is 3.64, ranking 362 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 65.85 and the support level at 46.53, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
56.679
Sell
MA10
57.304
Sell
MA20
56.872
Sell
MA50
61.026
Sell
MA100
67.323
Sell
MA200
70.488
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Spruce Biosciences Inc is 2.57, ranking 208 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 3.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
--
240-Day Volatility
--
Return
Best Daily Return
60 days
--
120 days
--
5 years
--
Worst Daily Return
60 days
--
120 days
--
5 years
--
Sharpe Ratio
60 days
--
120 days
--
5 years
--
Risk Assessment
Maximum Drawdown
240 days
--
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
--
3 years
--
5 years
--
Skewness
240 days
--
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
--
5 years
--
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
--
Maximum Daily Downside Volatility
60 days
--
Liquidity
Average Turnover Rate
60 days
--
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Spruce Biosciences Inc
SPRB
5.15 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
